Weekly dosing of fluoxetine for the continuation phase of treatment of major depression: Results of a placebo-controlled, randomized clinical trial

Journal of Clinical Psychopharmacology

Volumn 20, Issue 4, 2000, Pages 423-427

  Burke, William J ^a,b   Hendricks, Shelton E ^a   McArthur Miller, Delores ^a   Jacques, Daniel ^a   Bessette, Diane ^a   McKillip, Tracy ^a   Stull, Todd ^a   Wilson, James ^a  

^a UNIVERSITY OF NEBRASKA AT OMAHA   (United States)

^b 985580 Nebraska Medical Center ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; NORFLUOXETINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG TOLERABILITY; FEMALE; HAMILTON SCALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DEPRESSIVE DISORDER; DOUBLE-BLIND METHOD; FEMALE; FLUOXETINE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES;

EID: 0033912259     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-200008000-00006     Document Type: Article

References (20)

1. Gram LF. Fluoxetine. N Engl J Med 1994;331:1354-61.
2. Wernicke JF, Dunlop SR, Dornseif BE, Bosomworth JC, Humbert M. Low-dose fluoxetine therapy for depression. Psychopharmacol Bull 1988;24:183-8.
3. Wernicke JF, Dunlop SR, Dornseif BE, Zerbe RL. Fixed-dose fluoxetine therapy for depression. Psychopharmacol Bull 1987;23:164-8.
4. Beasley CM, Bosomworth JC, Wernicke JF. Fluoxetine. relationships among dose, response, adverse events, and plasma concentrations in the treatment of depression. Psychopharmacol Bull 1990;26:18-24.
5. Altamura AC, Montgomery SA. Fluoxetine dose, pharmacokinetics and clinical efficacy. Rev Contemp Pharmacother 1990;1:75-61.
6. Preskorn SH, Magnus RD. Inhibition of hepatic P-450 isoenzymes by serotonin selective reuptake inhibitors: in vitro and in vivo findings and their implications for patient care. Psychopharmacol Bull 1994;30:251-9.
7. Van Harten J. Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clin Pharmacokinet 1993;24:203-20.
8. Montgomery SA, James D, De Ruiter M. Weekly oral fluoxetine treatment of major depressive disorder. Presented at the 15th CINP Congress, Puerto Rico, 1986.
9. Montgomery SA, Baldwin D, Shah A, Green M, Fineberg N, Montgomery D. Plasma-level response relationships with fluoxetine and zimelidine. Clin Neuropharmacol 1990;13[suppl 2]:S71-S75.
10. Kupfer DJ. Long-term treatment of depression. J Clin Psychiatry 1991;52[suppl 5]:S28-S34.
11. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
12. Wong SH, Dellafera SS, Fernandes R. Determination of fluoxetine and norfluoxetine by high-performance liquid chromatography. J Chromatogr 1990;499:601-8.
13. Norman TR, Gupta RK, Burrows GD, Parker G, Judd FK Relationship between antidepressant response and plasma concentrations of fluoxetine and norfluoxetine. Int Clin Psychopharmacol 1993;8:25-9.
14. Amsterdam JF, Hornig-Rohan M, Rosenbaum JF, Quitkin FM, Fawcett J, Reimherr FW, Beasley CM. Fluoxetine and norfluoxetine plasma levels in major depression [abstract]. Biol Psychiatry 1995;37:606.
15. Prien RF, Kocsis JH. Long-term treatment of mood disorders. In: Bloom FE, Kupfer D, eds. Psychopharmacology: the fourth generation of progress. New York: Raven Press, 1995:1067-79.
16. Doogan DP, Caillard V. Sertraline in the prevention of depression. Br J Psychiatry 1992;160:217-22.
17. Montgomery SA, Dunbar G. Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression. Int Clin Psychopharmacol 1993;8:189-95.
18. Montgomery SA, Dufour H, Brion S, Gailledreau J, LaQueille X, Ferrey G, Moron P, Parant-Lucena N, Singer L, Danion JM, Beuzen JN, Pierredon MA. The prophylactic efficacy of fluoxetine in unipolar depression. Br J Psychiatry 1988;153[suppl 3]:69-76.
19. Frank E, Kupfer DJ, Perel JM, Cornes C, Jarrett DB, Malliinger AG, Thase ME, McEachran AB, Grochocinski VJ. Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1990;47:1093-9.
20. Kupfer DJ, Frank E, Perel JM, Cornes C, Mallinger AG, Thase ME, McEachran AB, Crochocinski VJ. Five-year outcome for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1992;49:769-73.